Complete report on H2 2015 pipeline review of Retinoblastoma with 20 market data tables and 13 figures, spread across 59 pages is available at
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs
to produce first-in-class and best-in-class products. Company Profiles discussed in this report includes BioLineRx, Ltd., Cellceutix Corporation, Icon Bioscience, Inc., Recombio S.L and RXi
Pharmaceuticals Corporation. Drugs Profiles discussed in this report includes BL-8040, FL-118X, KM-3174, melphalan, nutlin-3, racotumomab, RNAi Oligonucleotide Inhibiting MDM2 for
Retinoblastoma and Vaccine to Target TFDP3 for Oncology.
Scope of the report: The report provides a snapshot of the global therapeutic landscape of Retinoblastoma and reviews key players involved in the therapeutics development for Retinoblastoma
and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Retinoblastoma products under development by companies and
universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from
pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Retinoblastoma pipeline on the basis of target,
MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.
Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=457011 .
Featured News & Press Releases: Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of
Retinoblastoma. Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma. Aug 23,
2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma. Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of
Kevetrin In Retinoblastoma. Jan 03, 2013: Icon''s Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma.
List of Tables
Number of Products under Development for Retinoblastoma, H2 2015
Number of Products under Development for Retinoblastoma - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Retinoblastoma Therapeutics - Recent Pipeline Updates, H2 2015
Retinoblastoma - Dormant Projects, H2 2015
Another newly published market research titled Salivary Gland Cancer - Pipeline Review, H2 2015 provides comparative analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic
development for Salivary Gland Cancer and special features on late-stage and discontinued projects. Salivary Gland Cancer Pipeline Review Research Report of 59 pages is available at
Explore more reports on pharmaceuticals market and other disease pipelines at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research
studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
+ 1 888 391 5441
Connect With Us on:
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml